argenx SE (ARGX)
| Market Cap | 21.36B |
| Revenue (ttm) | 39.48M |
| Net Income (ttm) | -327.84M |
| Shares Out | 59.43M |
| EPS (ttm) | -5.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 342,390 |
| Open | 374.49 |
| Previous Close | 374.63 |
| Day's Range | 358.31 - 376.85 |
| 52-Week Range | 327.73 - 550.76 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 515.67 (+43.45%) |
| Earnings Date | May 9, 2024 |
About ARGX
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, ... [Read more]
Financial Performance
In 2023, argenx SE's revenue was 35.53 million, an increase of 254.41% compared to the previous year's 10.03 million. Losses were -295.05 million, -58.42% less than in 2022.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for ARGX stock is "Strong Buy." The 12-month stock price forecast is $515.67, which is an increase of 43.45% from the latest price.
News
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in second ...
argenx announces results of Annual General Meeting of Shareholders
May 7, 2024 – 5:30pm ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseas...
argenx to Present at BofA Securities 2024 Health Care Conference
May 7, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today annou...
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
May 2, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today annou...
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
ADHERE data show VYVGART ® Hytrulo has potential to be first advancement for CIDP patients in 30 years
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease
RHO study supports proof-of-concept in primary Sjogren's disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00 AM CET Amster...
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
VYVGART ® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP)
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts reflect real-world value and consistent efficacy and safety profile associated with long-term...
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
$374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART® Hytrulo for CIDP accepted for priority review by FDA with PDUFA target action date of June 21, 2...
argenx to Present at Upcoming Investor Conferences
February 26, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
February 22, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2024 If approved, VYVGART ® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP February 20, 2024, 7:00 AM...
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
Availability of VYVGART ® and self-administered VYVDURA demonstrates continued commitment to providing more choice and flexibility for gMG patients in Japan Jan. 18, 2024, 7:00 AM CET Amsterdam, the N...
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of argenx SE ("Ar...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of argenx SE ("Ar...
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of argenx SE ("Ar...
argenx Highlights 2024 Strategic Priorities
Reported $1.2 billion in preliminary* full-year 2023 global net product sales Submitted sBLA to FDA for VYVGART ® Hytrulo for CIDP with priority review voucher (PRV); if approved, launch expected mid-...
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Ti...
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of argenx SE ("A...
ONGOING INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against argenx SE and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 20, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of argenx SE ("A...
This biotech stock is down 25% on Wednesday: find out why
Argenx SE (NASDAQ: ARGX) says a late-stage trial of its candidate drug for an autoimmune condition failed to meet the primary or secondary endpoints. Its shares are down 25% at writing.
Argenx stock dives by a third after late-stage trial didn't meet goals
Argenx stock ARGX, -33.70% ARGX, -0.64% lost a third of its value as the Amsterdam biotech said a late-stage trial did not meet primary or secondary endpoints. The Phase 3 study was of using efgartigi...
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
ADDRESS study did not meet primary or secondary endpoints Pemphigus deprioritized as efgartigimod indication Update on BALLAD study GO/NO GO decision Conference call scheduled for today, December 20, ...
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
Regulated information – Inside information